Literature DB >> 27254086

Antenatal depression, treatment with selective serotonin reuptake inhibitors, and neonatal brain structure: A propensity-matched cohort study.

Shaili C Jha1, Samantha Meltzer-Brody2, Rachel J Steiner3, Emil Cornea4, Sandra Woolson5, Mihye Ahn6, Audrey R Verde2, Robert M Hamer7, Hongtu Zhu4, Martin Styner8, John H Gilmore9, Rebecca C Knickmeyer10.   

Abstract

The aim of this propensity-matched cohort study was to evaluate the impact of prenatal SSRI exposure and a history of maternal depression on neonatal brain volumes and white matter microstructure. SSRI-exposed neonates (n=27) were matched to children of mothers with no history of depression or SSRI use (n=54). Additionally, neonates of mothers with a history of depression, but no prenatal SSRI exposure (n=41), were matched to children of mothers with no history of depression or SSRI use (n=82). Structural magnetic resonance imaging and diffusion weighted imaging scans were acquired with a 3T Siemens Allegra scanner. Global tissue volumes were characterized using an automatic, atlas-moderated expectation maximization segmentation tool. Local differences in gray matter volumes were examined using deformation-based morphometry. Quantitative tractography was performed using an adaptation of the UNC-Utah NA-MIC DTI framework. SSRI-exposed neonates exhibited widespread changes in white matter microstructure compared to matched controls. Children exposed to a history of maternal depression but no SSRIs showed no significant differences in brain development compared to matched controls. No significant differences were found in global or regional tissue volumes. Additional research is needed to clarify whether SSRIs directly alter white matter development or whether this relationship is mediated by depressive symptoms during pregnancy.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Antidepressant; Depression; Diffusion tensor imaging; Fetal development; Infant, Newborn; Magnetic resonance imaging

Mesh:

Substances:

Year:  2016        PMID: 27254086      PMCID: PMC4930375          DOI: 10.1016/j.pscychresns.2016.05.004

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  46 in total

1.  A unified statistical approach for determining significant signals in images of cerebral activation.

Authors:  K J Worsley; S Marrett; P Neelin; A C Vandal; K J Friston; A C Evans
Journal:  Hum Brain Mapp       Date:  1996       Impact factor: 5.038

2.  Increasing use of antidepressants in pregnancy.

Authors:  William O Cooper; Mary E Willy; Stephen J Pont; Wayne A Ray
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

3.  Early-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.

Authors:  M E Glover; P C Pugh; N L Jackson; J L Cohen; A D Fant; H Akil; S M Clinton
Journal:  Neuroscience       Date:  2014-11-04       Impact factor: 3.590

4.  White matter changes in healthy adolescents at familial risk for unipolar depression: a diffusion tensor imaging study.

Authors:  Hao Huang; Xin Fan; Douglas E Williamson; Uma Rao
Journal:  Neuropsychopharmacology       Date:  2010-11-17       Impact factor: 7.853

5.  FADTTS: functional analysis of diffusion tensor tract statistics.

Authors:  Hongtu Zhu; Linglong Kong; Runze Li; Martin Styner; Guido Gerig; Weili Lin; John H Gilmore
Journal:  Neuroimage       Date:  2011-02-16       Impact factor: 6.556

6.  Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development.

Authors:  Yanling Xu; Youssef Sari; Feng C Zhou
Journal:  Brain Res Dev Brain Res       Date:  2004-06-21

7.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

8.  Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.

Authors:  Rebecca C Knickmeyer; Samantha Meltzer-Brody; Sandra Woolson; Robert M Hamer; J Keith Smith; Kenneth Lury; John H Gilmore
Journal:  Neuropsychopharmacology       Date:  2014-05-20       Impact factor: 7.853

9.  Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus.

Authors:  Y Kroeze; D Peeters; F Boulle; J L Pawluski; D L A van den Hove; H van Bokhoven; H Zhou; J R Homberg
Journal:  Transl Psychiatry       Date:  2015-09-22       Impact factor: 6.222

10.  Investigating white matter development in infancy and early childhood using myelin water faction and relaxation time mapping.

Authors:  Sean C L Deoni; Douglas C Dean; Jonathan O'Muircheartaigh; Holly Dirks; Beth A Jerskey
Journal:  Neuroimage       Date:  2012-08-02       Impact factor: 6.556

View more
  18 in total

1.  An experimental test of the fetal programming hypothesis: Can we reduce child ontogenetic vulnerability to psychopathology by decreasing maternal depression?

Authors:  Elysia Poggi Davis; Benjamin L Hankin; Danielle A Swales; M Camille Hoffman
Journal:  Dev Psychopathol       Date:  2018-08

2.  Perceptual interference processing in preschool children, with and without prenatal exposure to selective serotonin reuptake inhibitors.

Authors:  Tone Kristine Hermansen; Santeri Yrttiaho; Espen Røysamb; Annika Melinder
Journal:  Psychopharmacology (Berl)       Date:  2016-11-08       Impact factor: 4.530

Review 3.  Imaging structural and functional brain development in early childhood.

Authors:  John H Gilmore; Rebecca C Knickmeyer; Wei Gao
Journal:  Nat Rev Neurosci       Date:  2018-02-16       Impact factor: 34.870

4.  Exposure to prenatal maternal distress and infant white matter neurodevelopment.

Authors:  Catherine H Demers; Maria M Bagonis; Khalid Al-Ali; Sarah E Garcia; Martin A Styner; John H Gilmore; M Camille Hoffman; Benjamin L Hankin; Elysia Poggi Davis
Journal:  Dev Psychopathol       Date:  2021-12-07

5.  Proceedings of the 2017 annual meeting of the Fetal Alcohol Spectrum Disorders study group.

Authors:  Jeffrey R Wozniak; Anna Y Klintsova; Derek A Hamilton; Sandra M Mooney
Journal:  Alcohol       Date:  2017-11-01       Impact factor: 2.405

Review 6.  Prenatal exposures and infant brain: Review of magnetic resonance imaging studies and a population description analysis.

Authors:  Elmo P Pulli; Venla Kumpulainen; Jussi H Kasurinen; Riikka Korja; Harri Merisaari; Linnea Karlsson; Riitta Parkkola; Jani Saunavaara; Tuire Lähdesmäki; Noora M Scheinin; Hasse Karlsson; Jetro J Tuulari
Journal:  Hum Brain Mapp       Date:  2018-11-19       Impact factor: 5.038

7.  Maternal Anxiety and Depression during Late Pregnancy and Newborn Brain White Matter Development.

Authors:  R M Graham; L Jiang; G McCorkle; B J Bellando; S T Sorensen; C M Glasier; R H Ramakrishnaiah; A C Rowell; J L Coker; X Ou
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

8.  Associations Between Brain Structure and Connectivity in Infants and Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy.

Authors:  Claudia Lugo-Candelas; Jiook Cha; Susie Hong; Vanessa Bastidas; Myrna Weissman; William P Fifer; Michael Myers; Ardesheer Talati; Ravi Bansal; Bradley S Peterson; Catherine Monk; Jay A Gingrich; Jonathan Posner
Journal:  JAMA Pediatr       Date:  2018-06-01       Impact factor: 16.193

9.  Genome-Wide Association Analysis of Neonatal White Matter Microstructure.

Authors:  J Zhang; K Xia; M Ahn; S C Jha; R Blanchett; J J Crowley; J P Szatkiewicz; F Zou; H Zhu; M Styner; J H Gilmore; R C Knickmeyer
Journal:  Cereb Cortex       Date:  2021-01-05       Impact factor: 5.357

10.  Perinatal exposure to fluoxetine and maternal adversity affect myelin-related gene expression and epigenetic regulation in the corticolimbic circuit of juvenile rats.

Authors:  Anouschka S Ramsteijn; Rikst Nynke Verkaik-Schakel; Danielle J Houwing; Torsten Plösch; Jocelien D A Olivier
Journal:  Neuropsychopharmacology       Date:  2022-01-31       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.